Basque company becomes first authorised under new European SoHO rules
News
Exdensur approved in EU for severe asthma and CRSwNP
European Commission backs first ultra‑long‑acting biologic for respiratory disease
Axol Bioscience acquires Newcells Biotech ophthalmology unit
Move expands iPSC‑derived retinal model portfolio and strengthens position in research
Nuclera and leadXpro partner to accelerate structure‑based drug design
Collaboration aims to speed access to challenging targets through an AI‑guided workflow
Lundbeck reports positive phase 2b results for migraine prevention drug
Bocunebart shows significant reduction in monthly migraine days in patients with previous treatment failures
European life sciences coalition launched to boost investment ecosystem
New group aims to address structural barriers holding back Europe’s biotech scale‑up
99mtc‑maraciclatide granted fast track status for ILD imaging
FDA designation aims to speed development of new diagnostic tool
Bioxytran reports rapid viral clearance in phase 2 trial
ProLectin‑M achieves 100% viral elimination by day seven in placebo‑controlled study
Thx Pharma and Biocodex sign rare disease licensing deal
Biocodex secures rights to Batten-1 and TX01 in agreement worth up to €173 million
AstraZeneca bladder cancer therapy wins NICE backing
Regulator recommends durvalumab as first perioperative IO option for muscle‑invasive disease
Redefining trial access
Re:Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials
Strong clinical data for Breye lead asset danegaptide
Oral candidate shows favourable safety profile and signs of clinical activity in NPDR
EHP Awards triumph
Recognising the achievements of this year’s standout healthcare collaborations
Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
